Furthermore, Vincerx announced the termination of a previous sales agreement with Leerink Partners LLC and approved a reverse stock split, with the ratio to be determined later. These developments ...

Fintel reports that on April 8, 2025, Leerink Partners initiated coverage of Spyre Therapeutics (NasdaqGS:SYRE) with a Outperform recommendation. Analyst Price Forecast Suggests 353.70% Upside As ...

On Tuesday, Leerink Partners maintained its Outperform rating on CVS Health (NYSE:CVS) shares with a steady price target of $75.00. According to InvestingPro data, CVS Health, currently trading at $63 ...

That wound up well above expectations, Leerink Partners analyst Whit Mayo said in a research note. BTIG analyst David Larsen said separately that the final increase more than doubled what was ...

On Tuesday, Leerink Partners maintained its Outperform rating on CVS Health (NYSE:CVS) shares with a steady price target of $75.00. According to InvestingPro data, CVS Health, currently trading at ...

Shares of major health insurers jumped Tuesday after the federal government announced a better-than-expected 2026 payment increase for Medicare Advantage plans. The Centers for Medicare and ...

That wound up well above expectations, Leerink Partners analyst Whit Mayo said in a research note. BTIG analyst David Larsen said separately that the final increase more than doubled what was ...